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Abstract
Background: Caffeic acid (CA) and ellagic acid (EA) are phenolic acids naturally occurring in many
plant foods. Cardiac protective effects of these compounds against dyslipidemia, hypercoagulability,
oxidative stress and inflammation in diabetic mice were examined.
Methods: Diabetic mice were divided into three groups (15 mice per group): diabetic mice with
normal diet, 2% CA treatment, or 2% EA treatment. One group of non-diabetic mice with normal
diet was used for comparison. After 12 weeks supplement, mice were sacrificed, and the variation
of biomarkers for hypercoagulability, oxidative stress and inflammation in cardiac tissue of diabetic
mice were measured.
Results: The intake of CA or EA significantly increased cardiac content of these compounds,
alleviated body weight loss, elevated plasma insulin and decreased plasma glucose levels in diabetic
mice (p < 0.05). These treatments also significantly enhanced plasma antithrombin-III and protein
C activities (p < 0.05); and decreased triglyceride content in cardiac tissue and plasma (p < 0.05),
in which the hypolipidemic effects of EA were significantly greater than that of CA (p < 0.05). CA
or EA significantly lowered cardiac levels of malondialdehyde, reactive oxygen species, interleukin
(IL)-beta, IL-6, tumor necrosis factor (TNF)-alpha and monocyte chemoattractant protein (MCP)-
1 (p < 0.05); and retained cardiac activity of glutathione peroxidase (GPX), superoxide dismutase
(SOD) and catalase (p < 0.05). These compounds also significantly up-regulated cardiac mRNA
expression of GPX1, SOD and catalase; and down-regulated IL-1beta, IL-6, TNF-alpha and MCP-1
mRNA expression in diabetic mice (p < 0.05).
Conclusion: These results support that CA and EA could provide triglyceride-lowering, anti-
coagulatory, anti-oxidative, and anti-inflammatory protection in cardiac tissue of diabetic mice.
Thus, the supplement of these agents might be helpful for the prevention or attenuation of diabetic
cardiomyopathy.
Background
Diabetic cardiomyopathy, one of diabetic complications,
remains the major cause of mortality in people with dia-
betes [1]. Lipid disorder, coagulation predomination, oxi-
dative stress and inflammatory injury are important
factors responsible for the development of diabetic cardi-
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omyopathy because these factors promote the progression
of premature atherosclerosis, coronary insufficiency and
myocardial infarction [2]. The hypercoagulability
occurred in diabetic patients is due to the upregulation of
blood coagulation factors such as fibrinogen, and/or
downregulation of anticoagulation factors such as anti-
thrombin-III (AT-III) [2,3]. Diabetes associated oxidative
stress resulted from hyperglycemia-induced overproduc-
tion of free radicals and reactive oxygen species (ROS)
could cause necrosis and/or apoptosis in cardiomyocytes
[4,5]. In addition, disturbed balance between Th1 and
Th2 cytokines and overproduced pro-inflammatory
cytokines such as interleukin (IL)-1beta, tumor necrosis
factor (TNF)-alpha and monocyte chemoattractant pro-
tein-1 (MCP-1) enhance systemic inflammatory stress and
exacerbate diabetes associated cardiac dysfunctions [6,7].
Thus, any agent(s) with lipid-lowering, anti-coagulatory,
anti-oxidative and/or anti-inflammatory activities may
potentially prevent or delay the occurrence of diabetic car-
diomyopathy.
Caffeic acid and ellagic acid are phenolic acids naturally
occurring in many plant foods such as carrot, tomato,
strawberry and blueberry [8,9]. It has been documented
that these phenolic acids possess anti-oxidative activities
such as scavenging free radicals and chelating metal ions
[10,11]. Yamada et al. [12] reported that oral administra-
tion of caffeic acid resulted in the presence of its intact
form in mice liver. However, the information regarding
the accumulation of caffeic acid or ellagic acid in cardiac
tissue after dietary supplement is lacked. On the other
hand, the anti-diabetic effects of caffeic acid have been
examined [13,14]; and these authors observed that this
compound could decrease blood glucose level. So far, less
information is available regarding the anti-diabetic effect
of ellagic acid; and it also remains unknown that caffeic
acid or ellagic acid could protect cardiac tissue against dia-
betes associated dyslipidemia, hypercoagulability, oxida-
tive stress and inflammation.
The major purpose of this study was to investigate the
lipid-lowering, anti-coagulatory, anti-oxidative and anti-
inflammatory effects of caffeic acid and ellagic acid in car-
diac tissue of diabetic mice. Also, the impact of these com-
pounds on cardiac mRNA expression of antioxidant
enzymes and cytokines was examined. These results could
elucidate the possible action modes from these com-
pounds against diabetic cardiomyopathy.
Materials and methods
Materials
Caffeic acid (CA, 99%), ellagic acid (EA, 99.5%) and other
chemicals were purchased from Sigma Chemical Co. (St.
Louis, MO, USA). All chemicals used in measurements
were of the highest purity commercially available.
Animals
Male Balb/c mice, 3–4 wk old, were obtained from
National Laboratory Animal Center (National Science
Council, Taipei City, Taiwan). Mice were housed on a 12-
h light:dark schedule; water and mouse standard diet were
consumed ad libitum. The use of mice was reviewed and
approved by China Medical University animal care com-
mittee (CMU-97-22-N). To induce diabetes, mice with
body weights of 22.9 ± 0.8 g were treated with a single i.v.
dose (50 mg/kg) of streptozotocin dissolved in citrate
buffer (pH 4.5) into the tail vein of 12-h fasted mice. The
blood glucose level was monitored on d 5 and 10 from the
tail vein using a one-touch blood glucose meter (Lifescan,
Inc. Milpitas, CA, USA). Mice with fasting blood glucose
levels ≥ 14.0 mmol/l were used for this study.
Experimental design
CA or EA at 2 g was mixed with 98 g power diet containing
(g/100 g): 64 starch, 23 protein, 3.5 fat, 5 fiber, 1 vitamin
mixture and 3 salt mixture (PMI Nutrition International
LLC, Brentwood, MO, USA). After diabetes was induced,
mice were divided into three groups (15 mice per group):
diabetic mice with normal diet, diabetic mice with 2% CA
treatment, and diabetic mice with 2% EA treatment. One
group of non-diabetic mice with normal diet was used for
comparison. All mice had free access to food and water at
all times. Body weight, consumed water volume and food
were recorded. After 12 wk supplementation, mice were
sacrificed with carbon dioxide. Blood was collected, and
plasma was separated from erythrocytes immediately.
Cardiac tissue was removed and perfused for 2 min by
phosphate buffer saline (PBS, pH 7.2) to remove the
remaining blood. Cardiac tissue at 0.2 g was homoge-
nized on ice in 2 ml PBS, and the filtrate was collected.
The protein concentration of plasma or cardiac tissue fil-
trate was determined by the method of Lowry et al. [15]
using bovine serum albumin as a standard. In all experi-
ments, the sample was diluted to a final concentration of
1 g protein/l using PBS, pH 7.2.
Content of CA or EA in cardiac tissue
An HPLC method described in Yamada et al. [12] was
used to analyze the cardiac content of intact form of CA or
EA, in which an octadecylsilica column (4.6 × 250 mm,
Wakopak, Wako Pure Chemical Industry, Tokyo, Japan),
and a mobile phase consisting of 95.6% H2O, 4.1% ethyl
acetate and 0.3% acetic acid were used at 30°C with a flow
rate of 0.8 ml/min.
Assay of glucose, insulin, alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) activities
Plasma glucose level (mmol/l) was measured by a glucose
kit (Sigma Chemical Co., St. Louis, MO, USA). Plasma
insulin level (nmol/l) was measured by using a rat insulin
radioimmunoassay kit (SRI-13K, Linco Research Inc., St.Nutrition & Metabolism 2009, 6:33 http://www.nutritionandmetabolism.com/content/6/1/33
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Charles, MO, USA). For glucose and insulin, the intra
coefficients of variation (CVs) were 7.1 and 5.4%; and the
inter CVs were 6.3 and 5.8%. Serum activity of ALT and
AST were determined by using commercial assay kits
(Randox Laboratories Ltd., Crumlin, UK), their intra and
inter CVs were in the range of 2.5–4.6%.
Lipid analyses
Triglyceride (TG) and total cholesterol (TC) levels (g/l) in
plasma were determined by triglycerides/GB kit and cho-
lesterol/HP kit (Boehringer Mannheim, Germany),
respectively. For TG and TC, their intra CVs were 4.3 and
5.0%; and their inter CVs were 3.7 and 4.8%. Total lipids
were extracted from cardiac tissue, TG concentration (mg/
g wet tissue) was quantified by a colorimetric assay [16],
and total cholesterol (mg/g wet tissue) was measured
using o-phthalaldehyde [17].
Measurement of blood coagulation and anticoagulation 
factors
Blood samples were anticoagulated using sodium citrate
according to the protocols provided by the manufacturers
of the kits used. Plasma fibrinogen level (g/l) was meas-
ured based on the principle of salting out using a commer-
cial kit (Iatroset Fbg, Iatron Laboratory, Tokyo, Japan).
Plasminogen activator inhibitor-1 (PAI-1) activity (kU/l)
was assayed by a commercial kit (Trinity Biotech plc, Co.
Wicklow, Ireland). For fibrinogen and PAI-1, the intra and
inter CVs ranged from 5.4 to 6.7%. The activity (%) of AT-
III and protein C in plasma was determined by chromog-
enic assays according to the manufacturer'sinstruction s
using commercial AT-III and protein C kits (Sigma Chem-
ical Co., St. Louis, MO, USA), and was shown as ratio of
those in normal human plasma. For AT-III and protein C,
the intra CVs were 3.4 and 4.7%; and the inter CVs were
6.0 and 7.2%.
Determination of oxidative and anti-oxidative status
Glutathione (GSH) and oxidized glutathione (GSSG)
concentrations (nmol/mg protein) in cardiac tissue were
determined by commercial colorimetric GSH and GSSG
assay kits (OxisResearch, Portland, OR, USA). For GSH
and GSSG, the intra CVs were 5.0 and 5.8%; and the inter
CVs were 4.2 and 6.0%. Glutathione peroxidase (GPX),
catalase and superoxide dismutase (SOD) activities (U/
mg protein) in cardiac tissue were determined by com-
mercial assay kits (Calbiochem Inc., San Diego, CA, USA).
Their intra CVs were in the range of 6.3–7.5%; and inter
CVs were in the range of 5.9–7.8%. Lipid oxidation in car-
diac tissue was determined by measuring the level of
malondialdehyde (MDA, μmol/mg protein) via an HPLC
method [18]. The method described in Privratsky et al.
[19] was used to determine the amount of ROS in cardiac
tissue. Briefly, 10 mg cardiac tissue was homogenized in 1
ml of ice cold 40 mM Tris-HCl buffer (pH 7.4), and fur-
ther diluted to 0.25% with the same buffer. Then, samples
were loaded with 10 μmol/l 2', 7'-dichlorofluorescin at
37°C for 30 min. After rinsing, and the fluorescence
intensity was measured using a fluorescent microplate
reader with excitation wavelength at 480 nm and emis-
sion wavelength at 530 nm. Untreated samples were used
to determine background fluorescence.
Cardiac inflammatory factors analyses
Cardiac tissue was homogenized in 10 mM Tris-HCl buff-
ered solution (pH 7.4) containing
2 M NaCl, 1 mM ethylenediaminetetraacetic acid, 0.01%
Tween 80, 1 mM phenylmethylsulfonyl fluoride, and cen-
trifuged at 9000 × g for 30 min at 4°C. The resultant
supernatant was used for cytokine determination. The lev-
els of IL-1beta, IL-6, TNF-alpha, IL-4, IL-10 and MCP-1
were measured by ELISA using cytoscreen immunoassay
kits (BioSource International, Camarillo, CA, USA). Sam-
ples were assayed in duplicates according to manufac-
turer's instructions. The sensitivity of the assay, i.e., the
lower limit of detection, was 5 nmol/l for IL-1beta, IL-4,
IL-6, IL-10 and 10 nmol/l for TNF-alpha and MCP-1.
Real-time polymerase chain reaction (RT-PCR) for mRNA 
expression
RT-PCR was used to examine the cardiac mRNA expres-
sion of catalase, GPX1, SOD, IL-1beta, IL-6, TNF-alpha
and MCP-1. Cardiac tissue was homogenized in guanidi-
nethiocyanate, and RNA was extracted using TRIizol rea-
gent and further digested with DNase. Two μg of total
RNA was used to generate cDNA. Reverse transcription
was performed in a one-step protocol using the iScript
cDNA Synthesis Kit (Bio-Rad Co., Hercules, CA, USA)
according to the manufacturer's instructions. The primers
were as follows. Catalase: forward, 5'-TTC AGA AGA AAG
CGG TCA AGA AT-3', reverse, 5'-GAT GCG GGC CCC ATA
GTC-3'; GPX1: forward, 5'-CCC CAC TGC GCT CATGA-3',
reverse, 5'-GGC ACA CCG GAG ACC AAA-3'; Cu-Zn SOD:
forward, 5'-TGG GTT CCA CGT CCA TCA GTA-3',
reverse,5'-ACC GTC CTT TCC AGC AGT CA-3'; IL-1beta:
forward,5'-TGT GGC TGT GGA GAA GCT GT-3', reverse,
5'-CAG CTC ATA TGG GTC CGA GA-3'; IL-6: forward, 5'-
CAC GGC CTT CCC TAC TTC AC-3', reverse, TGC AAG
TGC ATC ATC GTT GT-3'; TNF-alpha: forward, 5'-ACT
CAA CAA ACT GCC CTT CTG AG-3', reverse, 5'-TTA CAG
CTG GTT TCG ATC CAT TT-3'; MCP-1: forward, 5'-CAG
GTC CCT GTC ATG CTT CT-3', reverse, 5'-CAC TGT CAC
ACT GGT CAC T-3'; glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH): forward, 5'-TGA TGA CAT CAA GAA
GGT GGT GAA G-3', reverse,5'-CCT TGG AGG CCATGT
AGG CCA T-3'. The target concentration was expressed rel-
ative to the concentration of a reference housekeeping
gene, GAPDH. PCR was conducted using the following
parameters: 50°C for 2 min, 95°C for 10 min and 40Nutrition & Metabolism 2009, 6:33 http://www.nutritionandmetabolism.com/content/6/1/33
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cycles at 94°C for 20 s and 60°C for 1 min. Generated flu-
orescence from each cycle was quantitatively analyzed by
using the Taqman system based on real-time sequence
detection system (ABI Prism 7700; Perkin-Elmer Inc., Fos-
ter City, CA, USA). In this present study, the mRNA level
of the control group (without diabetes and with normal
diet) was defined as 100%; then, mRNA level of other
groups were calculated as percentage of the control group.
Statistical analysis
All data were expressed as mean ± standard deviation
(SD). A statistical software package, SAS program (Version
5.1), was used to perform statistical analysis. One-way
analysis of variance (ANOVA), followed by Dunnett's t-
test was used to assess the significance of any change
between groups. Statistical significance is defined as p <
0.05.
Results
The content of CA or EA in cardiac tissue is shown in Table
1. Dietary supplement of these compounds significantly
increased their content in cardiac tissue of diabetic mice.
Water intake, food intake, body weight and serum levels
of ALT and AST at wks 1 and 12 are presented in Table 2.
Compared with diabetic mice with normal diet, mice with
CA and EA supplement had significantly lower water
intake, lower food intake and higher body weight at wk 12
(p < 0.05). CA or EA treatment did not affect serum activ-
ity of ALT and AST in diabetic mice (p > 0.05). Plasma lev-
els of glucose and insulin are presented in Figure 1.
Compared with diabetic mice with normal diet, CA and
EA treatments significantly decreased glucose level and
increased insulin level at wk 12 (p < 0.05). Plasma level of glucose (mmol/l) or insulin (nmol/l) of non- diabetic mice (Non-DM), diabetic mice consumed normal  diet (DM), 2% caffeic acid (CA) or ellagic acid (EA) at 1 and  12 week Figure 1
Plasma level of glucose (mmol/l) or insulin (nmol/l) of 
non-diabetic mice (Non-DM), diabetic mice con-
sumed normal diet (DM), 2% caffeic acid (CA) or 
ellagic acid (EA) at 1 and 12 week. Data are mean ± SD, 
n = 15. a-dMeans among bars without a common letter differ, 
p < 0.05.
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Table 1: Content of caffeic acid (CA) and ellagic acid (EA) in 
cardiac tissue from diabetic mice consumed normal diet (DM), 
2% CA or EA at 12 week. 
Cardiac tissue
(mg/100 g wet tissue)
DM DM+CA DM+EA
Caffeic acid -a 24.7 ± 2.3 -
Ellagic acid - - 29.5 ± 3.5
ameans too low to be detected.
Data are mean ± SD, n = 15.
Table 2: Water intake (WI, ml/mouse/d), food intake (FI, g/
mouse/d), body weight (BW, g/mouse), serum alanine 
aminotransferase activity (ALT, U/l), aspartate 
aminotransferase activity (AST, U/l) of non-diabetic mice (Non-
DM), diabetic mice consumed normal diet (DM), 2% caffeic acid 
(CA) or ellagic acid (EA) at 1 and 12 week. 
Non-DM DM DM+CA DM+EA
WI
1 2.5 ± 0.4a 3.6 ± 0.7a 3.1 ± 0.4a 3.2 ± 0.5a
12 3.0 ± 0.5a 7.9 ± 1.2c 5.6 ± 0.8b 6.0 ± 0.7b
FI
1 2.2 ± 0.6a 2.4 ± 0.5a 2.3 ± 0.7a 2.5 ± 0.6a
12 3.1 ± 1.0a 7.2 ± 1.3c 5.8 ± 0.8b 6.1 ± 0.9b
BW
1 22.9 ± 1.2b 20.6 ± 1.0a 21.0 ± 1.3a 21.2 ± 0.8a
12 29.7 ± 2.0d 11.5 ± 1.4a 16.2 ± 1.0c 14.7 ± 0.9b
ALT
15 2  ±  5 a 54 ± 7a 50 ± 3a 55 ± 4a
12 51 ± 6a 50 ± 5a 52 ± 7a 53 ± 5a
AST
17 5  ±  9 a 72 ± 4a 77 ± 5a 70 ± 7a
12 74 ± 6a 73 ± 8a 71 ± 5a 72 ± 4a
Data are mean ± SD, n = 15.
a-dMeans in a row without a common letter differ, p < 0.05.Nutrition & Metabolism 2009, 6:33 http://www.nutritionandmetabolism.com/content/6/1/33
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TG and TC content in cardiac tissue and plasma at wk 12
are shown in Table 3. CA and EA treatments significantly
lowered cardiac and plasma TG content (p < 0.05), in
which the effect of EA was greater than that of CA (p <
0.05). Both CA and EA failed to affect TC content in car-
diac tissue and plasma (p > 0.05). Plasma levels of coagu-
lation and anti-coagulation factors at wk 12 are shown in
Table 4. CA and EA treatments significantly elevated AT-III
and protein C activities (p < 0.05); but failed to affect PAI-
1 activity and fibrinogen level in diabetic mice (p > 0.05).
As shown in Table 5, CA or EA treatment significantly
decreased cardiac levels of MDA, ROS and GSSG in dia-
betic mice (p < 0.05); these supplements also significantly
increased cardiac GSH level and retained activity of GPX,
SOD and catalase (p < 0.05). Cardiac levels of cytokines
are presented in Table 6. CA or EA supplement signifi-
cantly reduced IL-1beta, IL-6, TNF-alpha and MCP-1 lev-
els (p < 0.05); but these compounds failed to affect cardiac
IL-4 and IL-10 levels (p > 0.05). The effects of CA or EA on
mRNA expression of cardiac catalase, SOD, GPX1, IL-
1beta, IL-6, TNF-alpha and MCP-1 are shown in Figure 2.
CA or EA treatment significantly up-regulated mRNA
expression of catalase, SOD and GPX1; and down-regu-
lated IL-1beta, IL-6, TNF-alpha and MCP-1 mRNA expres-
sion in cardiac tissue of diabetic mice (p < 0.05).
Discussion
Our present study revealed that the dietary supplement of
caffeic acid and ellagic acid increased cardiac content of
these compounds in their intact forms; and these treat-
ments effectively elevated insulin secretion, improved gly-
cemic control, decreased plasma and cardiac triglyceride
levels, diminished cardiac oxidative and inflammatory
stresses, and attenuated coagulation risk in diabetic mice.
These findings support that these agents could protect car-
diac tissue against the progression of diabetic cardiomy-
opathy via these triglyceride-lowering, anti-oxidative,
anti-coagulatory and anti-inflammatory effects.
We found that these compounds substantially elevated
insulin secretion, which might subsequently attenuate
dyslipidemia in CA or EA treated diabetic mice via
improving lipid metabolism. Thus, the observed lower
triglyceride accumulation in cardiac tissue and plasma
could be explained. Diabetes is a thrombosis-prone con-
dition because hyperglycemia-induced ROS causes plate-
let dysfunction, and insulin deficiency reduces the release
of thrombolytic enzymes such as tissue plasminogen acti-
vators [20]. Activated AT-III and protein C are important
anticoagulants because AT-III inhibits the activity of a
number of proteases in the coagulation cascade, and pro-
tein C inactivates coagulation factors such as factors Va
and VIIIa [21]. The results of our present study indicated
that caffeic acid or ellagic acid treatment markedly ele-
vated AT-III and protein C activities, which might conse-
quently enhance anticoagulatory activity and alleviate
diabetes associated hypercoagulability. These findings
support that these compounds could improve hemostatic
disorder and reduce the risk of diabetes associated athero-
Table 4: Coagulatory factors, PAI-1 activity and fibrinogen level; anti-coagulatory factors, AT-III and protein C in plasma from non-
diabetic mice (Non-DM), diabetic mice consumed normal diet (DM), 2% caffeic acid (CA) or ellagic acid (EA) at 12 week. 
Non-DM DM DM+CA DM+EA
PAI-1, kU/l 7.4 ± 0.7a 19.2 ± 1.3b 18.7 ± 1.4b 18.5 ± 1.0b
Fibrinogen, g/l 2.41 ± 0.19a 4.91 ± 0.27b 4.65 ± 0.30b 4.70 ± 0.21b
AT-III, % 138 ± 12c 70 ± 4a 98 ± 5b 104 ± 7b
Protein C, % 96 ± 6c 58 ± 5a 75 ± 7b 80 ± 6b
a-cMeans in a row without a common letter differ, p < 0.05.
Data are mean ± SD, n = 15.
Table 3: Level of triglyceride (TG) and total cholesterol (TC) in cardiac tissue and plasma from non-diabetic mice (Non-DM), diabetic 
mice consumed normal diet (DM), 2% caffeic acid (CA) or ellagic acid (EA) at 12 week. 
Non-DM DM DM+CA DM+EA
Cardiac tissue
TG, mg/g wet tissue 25.4 ± 1.8a 41.7 ± 2.3d 36.8 ± 1.7c 32.4 ± 2.0b
TC, mg/g wet tissue 2.9 ± 0.8a 4.2 ± 0.8b 4.0 ± 0.9b 3.9 ± 0.7b
Plasma
TG, g/l 2.24 ± 0.18a 4.16 ± 0.34d 3.51 ± 0.15c 3.04 ± 0.21b
TC, g/l 1.34 ± 0.23a 3.67 ± 0.31b 3.56 ± 0.26b 3.61 ± 0.23b
a-dMeans in a row without a common letter differ, p < 0.05.
Data are mean ± SD, n = 15.Nutrition & Metabolism 2009, 6:33 http://www.nutritionandmetabolism.com/content/6/1/33
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genesis and thrombosis via decreasing triglyceride level in
circulation and cardiac tissue as well as enhancing activity
of fibrinolytic factors such as AT-III and protein C. On the
other hand, fibrinogen is a precursor in fibrin formation
and a cofactor in platelet aggregation; PAI-1 is the primary
physiologic inhibitor of fibrinolysis [22]. Our present
study found that test compounds failed to affect fibrino-
gen level and PAI-1 activity in diabetic mice. Obviously,
these compounds could not attenuate hypercoagulability
via suppressing coagulatory factors such as fibrinogen and
PAI-1.
Diabetes is also an inflammation-prone condition
because hyperglycemia-induced ROS stimulates signal
transduction to elaborate inflammatory cytokines, e.g.
TNF-alpha, IL-1beta and IL-6 [23], which facilitates
inflammation, endothelial dysfunction, coagulation and
exacerbated the severity of diabetes [24,25]. Our present
study observed that caffeic acid or ellagic acid supplement
effectively suppressed cardiac mRNA expression of these
inflammatory cytokines, which contributed to diminish
cardiac inflammatory reactions in diabetic mice. These
results supported that these compounds were potent
agents against diabetes-associated cardiac inflammation.
We also notified that these compounds did not affect car-
diac levels of IL-4 and IL-10, anti-inflammatory and
immunosuppressive cytokines. Thus, the diminished dia-
betic cardiac inflammation from these agents was not due
to their stimulation on the production of anti-inflamma-
tory cytokines. It has been reported that elevated serum
MCP-1 level could serve as an inflammatory marker in
patients at risk for atherosclerotic vascular diseases
because MCP-1 is a chemotactic factor for activating
monocytes and macrophages, and could recruit mono-
cytes to the sites of injury [26,27]. In our present study,
the increased cardiac MCP-1 level indicated that these dia-
betic mice were at risk for cardio-vascular complications.
Meanwhile, we also found that the supplement of caffeic
acid and ellagic acid markedly lowered cardiac MCP-1
protein production in diabetic mice. These results indi-
cated that these compounds could protect cardiac tissue
against inflammation via decreasing the activation of
monocytes and macrophages, and lowering the recruit-
ment of monocytes.
It has been documented that caffeic acid and ellagic acid
possess non-enzymatic antioxidant activity such as scav-
enging free radicals, and enzymatic antioxidant activity
Table 5: Level of MDA, ROS, GSSG, GSH and activity of catalase, GPX, SOD in cardiac tissue from non-diabetic mice (Non-DM), 
diabetic mice consumed normal diet (DM), 2% caffeic acid (CA) or ellagic acid (EA) at 12 week. 
Non-DM DM DM+CA DM+EA
MDA, μmol/mg protein 0.63 ± 0.09a 3.17 ± 0.26d 1.45 ± 0.13b 1.97 ± 0.15c
ROS, nmol/mg protein 0.31 ± 0.09a 1.08 ± 0.13c 0.83 ± 0.07b 0.72 ± 0.10b
GSSG, nmol/mg protein 0.27 ± 0.07a 1.32 ± 0.12d 0.56 ± 0.07b 0.83 ± 0.05c
GSH, nmol/mg protein 18.9 ± 1.8d 10.6 ± 1.0a 14.6 ± 1.2c 12.0 ± 1.5b
GPX, U/mg protein 35.4 ± 2.6c 17.6 ± 1.2a 21.2 ± 2.0b 22.6 ± 2.3b
Catalase, U/mg protein 27.3 ± 2.0d 14.0 ± 0.9a 21.6 ± 1.8c 18.7 ± 1.5b
SOD, U/mg protein 30.7 ± 2.3d 16.9 ± 1.0a 23.1 ± 1.6c 19.1 ± 1.2b
a-dMeans in a row without a common letter differ, p < 0.05.
Data are mean ± SD, n = 15.
Cardiac mRNA expression of catalase, GPX1, SOD, IL-1beta,  IL-6, TNF-alpha and MCP-1 in mice without diabetes (Non- DM), diabetic mice consumed normal diet (DM), 2% caffeic  acid (CA) or ellagic acid (EA) at 12 week Figure 2
Cardiac mRNA expression of catalase, GPX1, SOD, 
IL-1beta, IL-6, TNF-alpha and MCP-1 in mice without 
diabetes (Non-DM), diabetic mice consumed normal 
diet (DM), 2% caffeic acid (CA) or ellagic acid (EA) at 
12 week. Data are mean ± SD, n = 15. a-dMeans among bars 
without a common letter differ, p < 0.05.
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such as increasing protein level of antioxidant enzymes
[10,28]. Our present study also observed that these com-
pounds could alleviate cardiac oxidative stress via reduc-
ing the formation of MDA and ROS; and enhance
antioxidant defense via increasing GSH retention and
restoring the activity of three antioxidant enzymes as well
as up-regulating cardiac mRNA expression of these anti-
oxidant enzymes. Therefore, it is highly possible that the
intake of these agents resulted in their accumulation in
cardiac tissue, which subsequently decreased cardiac oxi-
dative damage via their anti-oxidative activities. Then,
both inflammatory and coagulatory stresses in cardiac tis-
sue were alleviated because the available oxidants such as
ROS as inflammation and/or coagulation stimulators
were lowered.
Tasaki et al. [29] reported that dietary supplement of
ellagic acid up to 5% was safe in rats. Ellagic acid or caffeic
acid at 2% was sued in our present study, and we found
these compounds at this dose exhibited marked cardiac
protective effects and did not cause liver injury. Thus,
these agents at this dose might be safe for diabetic appli-
cation. Further study is necessary to verify the efficiency
and safety of these compounds before they are used for
human. It is interesting to find that caffeic acid was more
effective in increasing GSH content and enhancing cata-
lase and SOD activities; but ellagic acid was more effective
in lowering IL-6, TNF-alpha and MCP-1 levels in cardiac
tissue. Apparently, the cardiac protective action modes of
these two compounds were not identical.
Conclusion
Dietary supplement of caffeic acid and ellagic acid
improved glycemic control and lipid metabolism in dia-
betic mice. These compounds provided triglyceride-lower-
ing, anti-coagulatory, anti-oxidative and anti-
inflammatory protection for cardiac tissue of diabetic
mice. The impact of these agents on cardiac mRNA expres-
sion of antioxidant enzymes and cytokines revealed that
their protective effects occurred at transcription level.
Therefore, the supplement of these compounds might be
helpful for the prevention or alleviation of diabetic cardi-
omyopathy.
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